Orlistat response to missense mutations in lipoprotein lipase
Sign Up to like & getrecommendations! Published in 2017 at "Biotechnology and Applied Biochemistry"
DOI: 10.1002/bab.1500
Abstract: The human lipoprotein lipase (LPL) is a therapeutic target for obesity, and inhibition of LPL with the approved small molecule agent orlistat has been widely used in clinic to treat obesity‐related health problems such as… read more here.
Keywords: lipoprotein lipase; missense mutations; orlistat response; response missense ... See more keywords